anthralin/inflammation

Anthralin is the most common therapeutic agent among a small number of pro-oxidant, 9-anthrones effective in the topical treatment of psoriasis. However, the usefulness of this drug is diminished by toxic side effects, including skin irritation and inflammation. The activities of anthralin are

The inflammatory dose-response to anthralin was measured in human skin 24 h after pretreatment with topical corticosteroids and anthralin, and 48 h after removal of the stratum corneum with adhesive tape. Anthralin inflammation was increased after 1% hydrocortisone application and decreased by 0.1%

The effect of application site on anthralin inflammation was measured at 10 clinically normal volar skin sites on each forearm of 31 subjects as the increase in skin thickness at 48 h using Harpenden calipers. Pre-treatment and increase in skin thickness were significantly related to application

Application of 1% potassium hydroxide (KOH) reduced subsequent development of anthralin inflammation without loss of its therapeutic effect on psoriasis. Teepol had a similar but smaller effect on subsequent development of inflammation. The action of KOH appears to have resulted from enhanced

1 The effect of topical arachidonic acid on anthralin inflammation was studied using sequential measurements of erythema (reflectance photometry) and oedema (calipers). 2 Topical arachidonic acid in concentrations which produced a small short-lived inflammatory response greatly augmented the initial

Anthralin inflammatory oedema was measured using Harpenden calipers on psoriatic plaque and clinically uninvolved skin 6-48 h after anthralin application. There was a highly significant reduction in oedema response on the psoriatic plaque compared with the uninvolved skin (P less than 0.001). Both

The effect of prostaglandin inhibition, using topical indomethacin, on anthralin inflammation was studied. Indomethacin gel and gel base were applied to opposite flexor forearm skin sites of 11 volunteers for 2 h and then washed off. Anthralin and UVB were then applied to the gel-treated skin and

The effect of topical clobetasol propionate and a 1% topical indomethacin gel which could inhibit UV erythema was measured on anthralin inflammation by change in skin-fold thickness and erythema. The time course of the inflammatory oedema and erythema were different, as was their response to the

Twenty patients with chronic plaque psoriasis were treated with short-contact anthralin followed by 10% triethanolamine application to one side of the body and aqueous cream to the other. Anthralin-induced inflammation was inhibited on the triethanolamine-treated side whereas anthralin therapy had

The effect of terfenadine, an H1-receptor antagonist, on anthralin inflammation was studied in 12 subjects. Subjects were randomised to receive terfenadine 60 mg or placebo b.d. in a double-blind, cross-over study. Anthralin 5, 10 and 20 micrograms in 10 microliters chloroform was pipetted onto

Twenty-two primary, secondary, and tertiary amines were studied to determine whether they could reduce anthralin-induced inflammation. Amine solutions of 0.18 mol/L were applied after anthralin application to normal forearm skin. Inflammation was measured with the use of Harpenden calipers by the

We performed this study to determine the relationship between activation of nuclear factor (NF)-kappaB and inhibition of keratinocyte growth by anthralin, which not only might be useful for a better understanding of the role of NF-kappaB in the pathogenesis of psoriasis, but also indicate whether

Anthralin has been applied in low and high concentrations with and without UV-irradiation in the treatment of psoriasis (Schauder & Mahrle, 1982a,b). We have studied the relationship between the sensitivity to anthralin and UV-irradiation which might possibly help us to give a more individually